{"batchcomplete": "", "query": {"normalized": [{"from": "Gerhard_Domagk", "to": "Gerhard Domagk"}], "pages": {"474958": {"pageid": 474958, "ns": 0, "title": "Gerhard Domagk", "revisions": [{"slots": {"main": {"contentmodel": "wikitext", "contentformat": "text/x-wiki", "*": "{{Use dmy dates|date=August 2020}}\n{{Infobox scientist\n| name              = Gerhard Domagk\n| image             = Gerhard Domagk nobel.jpg\n| birth_name        = Gerhard Johannes Paul Domagk\n| birth_date        = {{Birth date|1895|10|30|df=yes}}\n| birth_place       = Lagow, [[Province of Brandenburg|Brandenburg]], [[Kingdom of Prussia]], [[German Empire]]<br>(now [[\u0141ag\u00f3w, \u015awiebodzin County]], [[Lubusz Voivodeship]], [[Poland]])\n| death_date        = {{Death date and age|df=yes|1964|04|24|1895|10|30}}\n| death_place       = Burgberg, [[Baden-W\u00fcrttemberg]], [[West Germany]]\n| residence         = \n| citizenship       = \n| nationality       = [[Germany|German]]\n| alma_mater        = [[University of Kiel]]\n| doctoral_advisor  = \n| doctoral_students = \n| known_for         = Discovery of [[Sulfonamide (medicine)|sulfonamides]] such as [[Prontosil]] as [[antibiotics]]<ref>{{Cite journal \n| doi = 10.1093/jac/17.6.689 | last1 = Otten | first1 = H. | title = Domagk and the development of the sulphonamides | journal = The Journal of Antimicrobial Chemotherapy | volume = 17 | issue = 6 | pages = 689\u2013696 | year = 1986 | pmid = 3525495| doi-access = free }}</ref>\n| influences        = \n| influenced        = \n| signature         = \n| footnotes         = \n| spouse            = Gertrud Strube\n| children          = One daughter and three sons\n| ethnicity         = \n| field             = [[Bacteriology]]\n| work_institutions = \n| prizes            = [[Cameron Prize for Therapeutics of the University of Edinburgh]] {{small|(1939)}}<br>[[Nobel Prize in Physiology or Medicine|Nobel Prize in Medicine]] {{small|(1939)}}<br>[[Paul Ehrlich and Ludwig Darmstaedter Prize]] {{small|(1956)}}<br>[[Fellow of the Royal Society]] {{small|(1959)}}<ref name=\"frs\"/>\n| religion          = \n}}\n'''Gerhard Johannes Paul Domagk''' ({{IPA-de|\u02c8\u0261e\u02d0\u0250\u032fha\u0281t \u02c8do\u02d0mak|-|De-Gerhard Domagk.ogg}}; 30 October 1895 \u2013 24 April 1964) was a German [[pathologist]] and [[bacteriologist]]. He is credited with the discovery of [[Sulfonamide (medicine)|sulfonamidochrysoidine]] (KL730) as an [[antibiotic]] for which he received the 1939 [[Nobel Prize in Physiology or Medicine]]. The drug became the first commercially available [[antibiotic]] and marketed under the brand name [[Prontosil]].<ref>{{Cite journal |last1=Kyle |first1=R. A. |last2=Shampo |first2=M. A. |year=1982 |title=Gerhard Domagk |journal=JAMA: The Journal of the American Medical Association |volume=247 |issue=18 |pages=2581 |doi=10.1001/jama.247.18.2581 |pmid=7040718}}</ref><ref>{{Cite journal |year=1964 |title=G. Domagk |journal=British Medical Journal |volume=1 |issue=5391 |pages=1189\u20131191 |doi=10.1136/bmj.1.5391.1189 |pmc=1813461 |pmid=14120818}}</ref> \n\nWhile working in the pathology department of the [[University of M\u00fcnster]], Domagk was invited to join the [[IG Farben]] branch at Elberfeld (later [[Wuppertal]]) in 1927. His duty was to test chemical compounds prepared at the IG Farben laboratory for potential drugs. A novel compound synthesised by Friedrich Mietzsch and Joseph Klarer, a benzene derivative of [[azo dye]] attached with [[sulphonamide]] group as a [[side chain]] was found to have antibacterial activity against human bacterium ''[[Streptococcus pyogenes]].'' In 1935, Domagk's only daughter, Hildegarde, injured herself and contracted a [[streptococcal infection]]. In a desperate attempt to save her daughter's arm from amputation and her life, Domagk used the new compound that eventually cured the infection. Given the brand name Prontosil, the new drug became the first antibiotic commercially available for bacterial infections.\n\nDomagk was chosen to receive the 1939 Nobel Prize in Physiology or Medicine \"for the discovery of the antibacterial effects of prontosil,\"<ref>{{Cite journal |last1=Raju |first1=T. N. |year=1999 |title=The Nobel chronicles. 1939: Gerhard Domagk (1895\u20131964) |journal=Lancet |volume=353 |issue=9153 |page=681 |doi=10.1016/S0140-6736(05)75485-4 |pmid=10030374 |s2cid=54410112}}</ref> but the [[Nazi Germany]] prohibited him from receiving the award. In 1947, after the fall of Nazi Germany, he was officially given the Nobel diploma and delivered the Nobel lecture.<ref name=\"nobel1939\">{{cite web|url=http://nobelprize.org/nobel_prizes/medicine/laureates/1939/|title=The Nobel Prize in Physiology or Medicine 1939 Gerhard Domagk|publisher=Nobelprize.org|access-date=2010-07-02}}</ref>\n\n==Biography==\nDomagk was born in [[\u0141ag\u00f3w, \u015awiebodzin County|Lagow]], [[Province of Brandenburg|Brandenburg]], German Empire (now Poland). His father Paul Richard Domagk was a school teacher. He had an elder brother Erich, who died in childhood, and a younger sister, Charlotte. When he was five, in 1900, his father was transferred to Sommerfeld (now [[Lubsko]], Poland). He immediately entered the Bismarck School where he completed elementary education in 1910. Then, he attended Herzog-Heinrich School in Liegnitz where he completed secondary education in 194, aged 14.<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Gerhard Domagk: The First Man to Triumph Over Infectious Diseases |date=2004 |publisher=LIT Verlag M\u00fcnster |isbn=978-3-8258-6164-3 |pages=8\u20139 |language=en}}</ref>\n\nDomagk entered the [[University of Kiel]] in 1914 to study medicine. As the [[First World War]] broke out, the university was closed and he returned to Sommerfeld. He joined the German Grenadier Regimen 7 as a volunteer along with 15 of his old school friends. In his first experience of war at Flanders in October 1914, he barely escaped death where 11 of his school friends were killed. He was transferred to eastern front in Poland in December 1914, where he was shot on the head.<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=12\u201313 |isbn=9783825861643 |language=en}}</ref> He was transported to Lichterfelde near Berlin where he recovered from the injury. There he was given a training as medical orderly. In May 1915, he rejoined the eastern front as a medic. He recalled the horrors and suffering, especially of infections, at the battlefields, saying \"There horrible impressions kept pursuing me during my whole life, and made me think how I could take measures against bacteria... I then swore, in case I would return to my home alive, to work and work to make a small contribution to solve that problem.\"<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=14\u201315 |isbn=9783825861643 |language=en}}</ref>\n\nAs the war ended in November 1918, Domagk resumed his medical course at Kiel. His doctoral thesis titled ''Beeinflussung der Kreatininausscheidung durch Muskelarbeit<ref>{{Cite book |last=Domagk |first=Gerhard |title=Beeinflussung der Kreatininausscheidung durch Muskelarbeit |publisher=Universit\u00e4t Kiel |year=1921 |oclc=793770685}}</ref>'' (''Influence of Creatinine Excretion in the Urine through Muscular Activity'')<ref name=\":0\">{{Cite journal |last1=Uhlendahl |first1=Hendrik |last2=Gross |first2=Dominik |date=2020 |title=Victim or profiteer? Gerhard Domagk (1895-1964) and his relation to National Socialism |url=https://pubmed.ncbi.nlm.nih.gov/32303387 |journal=Pathology, Research and Practice |volume=216 |issue=6 |pages=152944 |doi=10.1016/j.prp.2020.152944 |issn=1618-0631 |pmid=32303387|s2cid=215810336 }}</ref> was supervised by Max Buerger and with that he earned his degree in 1921.<ref name=\":1\" /> Between 1922 and 1923, he worked as an assistant to Georg Hoppe-Seyler at Kiel.<ref name=\":0\" />\n\nIn 1923, he met Walter Gross, the Director of the Institute of Pathology at the [[University of Greifswald]], at the conference of German Society of Pathology in Leipzig. Gross was impressed with him and appointed him a junior doctor at Greifswald.<ref name=\":1\">{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=16\u201318 |isbn=9783825861643 |language=en}}</ref> He supported Domagk's research on phagocytosis, an immune process discovered by Russian zoologist [[Elie Metchnikoff]], so far as permitting excessive use of electricity, constant photographic lights, and free roaming of experimental mice, all of which angered the janitor. Domagk's thesis \"Destroying infectious diseases through the reticuloendothelium and the development of amyloid\",<ref name=\":0\" /> published in 1924 in ''Virchows Archiv f\u00fcr pathologische Anatomie und Physiologie und f\u00fcr klinische Medizin'' (now ''[[Virchows Archiv]]'')<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1924 |title=Untersuchungen \u00fcber die Bedeutung des retikuloendothelialen Systems f\u00fcr die Vernichtung von Infektionserregern und f\u00fcr die Entstehung des Amyloids |url=http://link.springer.com/10.1007/BF01994397 |journal=Virchows Archiv f\u00fcr Pathologische Anatomie und Physiologie und f\u00fcr Klinische Medizin |language=de |volume=253 |issue=3 |pages=594\u2013638 |doi=10.1007/BF01994397 |s2cid=10695542 |issn=0945-6317}}</ref> was assessed as a worthy criterion for promotion to a full professor. However, Gross was appointed to the [[University of M\u00fcnster]], and he invited Domagk to join him as a lecturer at his proposed Department of Experimental Pathology.<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=21\u201322 |isbn=9783825861643 |language=en}}</ref> \n\nIn 1925, he married Gertrude Strube, at the time an advisor to the German Chamber of Commerce in Basel.<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=18 |isbn=9783825861643 |language=en}}</ref> Later they had three sons and a daughter.<ref name=\":0\" />\n\nAt M\u00fcnster, Domagk felt that the new department was not flourishing as he anticipated and was underpaid. The [[IG Farben]] branch at Elberfeld (later [[Wuppertal]]) noticed him and offered him to lead their institute of experimental pathology. When he informed of this opportunity to his university authority in July 1927, and that he would stay if at least he was given a position of associate professor; he never received a response. He took a sabbatical leave for two years without pay, and decided to accept IF Farben's offer in 1929.<ref>{{Cite book |last=Grundmann |first=Ekkehard |url=https://books.google.com/books?id=sg1QAwAAQBAJ |title=Ibid. |date=2004 |pages=26 |isbn=9783825861643 |language=en}}</ref> However, another source states that he joined the IG Farben in 1927.<ref name=\":0\" />\n\nDomagk was appointed director of the Institute of Pathology and Bacteriology, started working at the IG Farben laboratories at Wuppertal where he continued the studies of Josef Klarer and Fritz Mietzsch, based on works by [[Paul Ehrlich]], to use [[dye]]s, at that time a major product of the company, as [[antibiotic]]s. He changed his focus to [[tuberculosis]] and [[chemotherapy]]. He remained in that position until his retirement in 1961.<ref name=\":0\" />  \n\nDomagk died from heart attack at his villa in the Black Forest village of Burberg near [[K\u00f6nigsfeld im Schwarzwald|K\u00f6nigsfeld, Schwarzwald]].<ref name=\":9\">{{Cite news |date=1964-04-26 |title=Prof. Gerhard Domagk Dead; Won '39 Nobel Prize for Drug; Developed Prontosil, the First Sulfonamide \u2014 Studied Cancer and TB |language=en-US |work=The New York Times |url=https://www.nytimes.com/1964/04/26/archives/prof-gerhard-domagk-dead-won-39-nobel-prize-for-drug-developed.html |access-date=2022-10-05 |issn=0362-4331}}</ref> \n\n==Achievements==\n[[File:Tube of Prontosil tablets, Germany, 1935-1950 Wellcome L0057805.jpg|thumb|Tube of Prontosil tablets available in Germany during 1935-1950]]\n\n=== Prontosil ===\nDomagk's responsibility at IG Farben was to test the new compounds, [[Dye|chemical dyes]], for antimicrobial activities. Werner Schulemann, Friedrich Mietzsch, Hans Mauss and Joseph Klarer were largely responsible for providing a continuous supply of chemicals to be screened.<ref name=\":2\">{{Cite journal |last1=Wainwright |first1=Mark |last2=Kristiansen |first2=Jette E. |date=2011 |title=On the 75th anniversary of Prontosil |url=https://linkinghub.elsevier.com/retrieve/pii/S0143720810001853 |journal=Dyes and Pigments |language=en |volume=88 |issue=3 |pages=231\u2013234 |doi=10.1016/j.dyepig.2010.08.012}}</ref> Since the end of the 19th century, [[azo dyes]], developed and used for colouring textile and other materials, were found to have medicinal properties against infections. For example, German biologist [[Paul Ehrlich]] used [[methylene blue]], a type of azo dye, to kill [[Plasmodium|malarial parasites]] in experimental animals, and cured two persons from malaria in 1891. Later, Ehrlich and his students found that some azo dyes were effective against [[African sleeping sickness]].<ref name=\":3\" /> In 1913, P. Eisenberg discovered that another azo dye, chrysoidine could kill bacteria and could be used as a disinfectant.<ref>{{Cite journal |last=Whitson |first=Theodore C. |date=1968 |title=Development of topical chemotherapy in the management of burns |url=https://linkinghub.elsevier.com/retrieve/pii/0002961068904200 |journal=The American Journal of Surgery |language=en |volume=116 |issue=1 |pages=69\u201372 |doi=10.1016/0002-9610(68)90420-0|pmid=5652361 }}</ref><ref>{{Cite journal |last=Durie |first=Beatrix |date=1938 |title=Sulphanamide |url=https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.1938.tb46024.x |journal=Medical Journal of Australia |language=en |volume=2 |issue=27 |pages=1103\u20131109 |doi=10.5694/j.1326-5377.1938.tb46024.x |issn=0025-729X}}</ref> Following such leads, IG Farben devoted to studying and chemically modifying azo dyes for potential medicines.<ref name=\":3\">{{Cite journal |last=Wainwright |first=Mark |date=2008 |title=Dyes in the development of drugs and pharmaceuticals |url=https://linkinghub.elsevier.com/retrieve/pii/S0143720807000265 |journal=Dyes and Pigments |language=en |volume=76 |issue=3 |pages=582\u2013589 |doi=10.1016/j.dyepig.2007.01.015}}</ref>\n\n==== Development ====\nIn early 1930s, Mietzsch and Klarer synthesised a benzene derivative of azo dye, which was chemically related to (an analogue of) chrysoidine.<ref name=\":6\">{{Cite journal |last=Kenny |first=Meave |date=1945 |title=Chemotherapy in Obstetrics and Gynaecology |url=https://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.1945.tb07639.x |journal=BJOG: An International Journal of Obstetrics and Gynaecology |language=en |volume=52 |issue=4 |pages=372\u2013388 |doi=10.1111/j.1471-0528.1945.tb07639.x |issn=1470-0328 |s2cid=71576734}}</ref>  The compound had an addition of [[sulphonamide]] group as a side chain, thus becoming sulfamidochrysoidine. They suspected that a unique chemical component of sulphonamide group in the new dye could be a possible drug candidate; as Mietzsch predicted: \"[The sulphonamide parts were] the right substituents in the right positions on the azo group.\"<ref name=\":2\" /> The compound was then labelled KL730 (KL for Klarer). IG Farben received a German patent for the new compound in 1932.<ref name=\":5\">{{Cite journal |last=Chung |first=King-Thom |date=2016 |title=Azo dyes and human health: A review |url=https://pubmed.ncbi.nlm.nih.gov/27635691 |journal=Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews |volume=34 |issue=4 |pages=233\u2013261 |doi=10.1080/10590501.2016.1236602 |issn=1532-4095 |pmid=27635691|s2cid=27970581 }}</ref> \n\nThe exact date of synthesis is unknown.<ref name=\":6\" /> An account that the IG Farben leader Heinrich H\u00f6rlein suggested the use of sufur group to azo dyes \"some time in 1932\"<ref name=\":10\">{{Cite journal |last=Bentley |first=Ronald |date=2009 |title=Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams) |journal=Journal of Industrial Microbiology & Biotechnology |volume=36 |issue=6 |pages=775\u2013786 |doi=10.1007/s10295-009-0553-8 |issn=1476-5535 |pmid=19283418 |doi-access=free}}</ref> may not be true, as IG Farben received the patent of the first modified sulfamidochrysoidine on 7 November 1931.<ref name=\":11\">{{Cite journal |last=Brownlee |first=George |date=1949 |title=The Sulphonamides and Allied Compounds |url=https://www.nature.com/articles/163662a0 |journal=Nature |language=en |volume=163 |issue=4148 |pages=662 |doi=10.1038/163662a0 |bibcode=1949Natur.163..662B |s2cid=4120072 |issn=1476-4687}}</ref> The other related compound received patent  in December 1932.<ref name=\":5\" /> Initial experiments in 1931 indicated poor antibacterial effect against bacterial cultures. It was not known at the time that the active component of Prontosil was the sulphonamide and not the azo group, as they expected. In addition, the sulphonamides by themselves were not antibacterials, but only became active drug after metabolism inside the body. This is why the first tests (''in vitro'') on bacterial cultures failed.<ref name=\":5\" />\n\n==== Discovery of antibacterial activity ====\nIn early 1931,<ref name=\":11\" /> Domagk immediately tested the compound in mice that were having bacterial infection, and found that it was effective against Gram-positive bacteria.<ref name=\":4\" /> He designated a code for the compound D 4145 (D for Domagk).<ref name=\":10\" /> He induced infection at the belly ([[peritonitis]]) of mice using clinical specimens (isolates) of ''[[Streptococcus pyogenes]]''. In the first experiment, he infected 26 mice by injecting the bacteria, and he injected a single dose of Prontosil to 12 of the infected mice, while the rest 14 were simply kept infected (as [[Scientific control|controls]]) without Prontosil treatment. All the Prontosil-injected mice survived, meaning they were cured of the streptococcal infection,<ref name=\":2\" /><ref name=\":7\">{{Cite journal |last=Wong |first=Sam |date=2017 |title=Sibling saviours of the maternity ward |url=https://www.sciencedirect.com/science/article/pii/S0262407917302282 |journal=New Scientist |language=en |volume=233 |issue=3111 |pages=40\u201341 |doi=10.1016/S0262-4079(17)30228-2 |bibcode=2017NewSc.233...40W |issn=0262-4079}}</ref> whereas the untreated 14 mice all died by the fourth day of experiment.<ref name=\":6\" /> There were several more experimental tests, and a clinical trial in which a boy was cured of streptococcal infection in 1933.<ref name=\":2\" /> In February 1935, Domagk reported his experiments in the journal ''Deutsche Medizinische Wochenschrift''  as \"Ein Beitrag zur Chemotherapie der bakteriellen Infektionen\" (\"A contribution to the chemotherapy of bacterial infections\").<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1935 |title=Ein Beitrag zur Chemotherapie der bakteriellen Infektionen |url=http://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1129486 |journal=DMW - Deutsche Medizinische Wochenschrift |language=de |volume=61 |issue=7 |pages=250\u2013253 |doi=10.1055/s-0028-1129486 |issn=0012-0472}}</ref><ref name=\":5\" />\n\nAt the time, there was no medical cure for streptococcal infection, and infected body parts had to be surgically removed to prevent further spread of the infection.<ref>{{Cite journal |last=Estes |first=W. L. |date=1925 |title=Amputations in industrial surgery |journal=Annals of Surgery |volume=81 |issue=1 |pages=164\u2013190 |doi=10.1097/00000658-192501010-00016 |issn=0003-4932 |pmc=1400175 |pmid=17865165}}</ref> This is stil in practice when the infection had caused severe tissue damage even after antibiotics are available.<ref>{{Cite journal |last1=Sutherland |first1=Mark E. |last2=Meyer |first2=Anthony A. |date=1994 |title=Necrotizing Soft-Tissue Infections |url=https://linkinghub.elsevier.com/retrieve/pii/S0039610916463310 |journal=Surgical Clinics of North America |language=en |volume=74 |issue=3 |pages=591\u2013607 |doi=10.1016/S0039-6109(16)46331-0|pmid=8197532 }}</ref> In a notable incidence, Domagk's four-year-old daughter, Hildegarde, injured herself with a stitching needle while making Christmas decorations on 4 December 1935. She fell on the stairs and stabbed her hand with the needle, and the broken needle was stuck in her wrist. The needle was removed at a hospital. However, she developed severe inflammation and fever from the next day. As Domagk recounted:<blockquote>When the dressing was changed a few days later there was marked swelling of the hand, and despite removal of all the stitches the fever continued to rise rapidly. In spite of numerous incisions the inflammation phlegmon extended to the under-arm. A serious worsening of the general condition and dizziness occurred, so that we were gravely worried about the child. Since further surgical intervention was not possible, I asked permission of the treating surgeon to use Prontosil, after I had established by culture that streptococci were the cause of the illness.<ref>{{Cite journal |last=Petri |first=William A. |date=2007-04-04 |title=The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine |url=http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.297.13.1494 |journal=JAMA |language=en |volume=297 |issue=13 |doi=10.1001/jama.297.13.1494 |issn=0098-7484}}</ref> </blockquote>After making 14 incisions, the physician suggested that the only way to save Hildegarde was [[amputation]] of the arm. However, Hildegarde recovered following the Prontosil treatment and her arm was saved.<ref name=\":5\" /> \n\nBy 1935, Mietzsch and Klarer had prepared two forms of the compound, one is poorly soluble in water while the other is highly soluble. The water-soluble compound was given a name Streptozon (specifically Streptozon S, for the soluble sodium salt) after the bacterium with which it was originally experimented, and the less water-soluble was called Prontosil (specifically Prontosil rubrum).<ref>{{Cite journal |last=Braasch |first=William F. |date=1939 |title=Present status of chemotherapy for infections of the urinary tract |url=https://linkinghub.elsevier.com/retrieve/pii/S000296103990471X |journal=The American Journal of Surgery |language=en |volume=45 |issue=3 |pages=472\u2013478 |doi=10.1016/S0002-9610(39)90471-X}}</ref> Prontosil was used as the common name for both and the brand name of the drug after 1935. Domagk had used only the Streptozon type.<ref name=\":8\">{{Cite journal |last1=Colebrook |first1=Leonard |last2=Kenny |first2=M\u00e9ave |date=1936 |title=Treatment of Human Puerperal Infections, and of Experimental Infections in Mice, with Prontosil |url=https://linkinghub.elsevier.com/retrieve/pii/S014067360120734X |journal=The Lancet |language=en |volume=227 |issue=5884 |pages=1279\u20131281 |doi=10.1016/S0140-6736(01)20734-X}}</ref> He reported the development of the drug and his human application in article \"Chemotherapie der streptokokken-infektionen\" (\"Chemotherapy of streptococcus infection\") in the October issue of ''Klinische Wochenschrift'' (later ''[[Journal of Molecular Medicine]]'')''.''<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1936 |title=Chemotherapie der Streptokokken-Infektionen |url=http://link.springer.com/10.1007/BF01780820 |journal=Klinische Wochenschrift |language=de |volume=15 |issue=44 |pages=1585\u20131590 |doi=10.1007/BF01780820 |s2cid=5722987 |issn=0023-2173}}</ref>\n\n==== Confirmation ====\nThe first independent research was done by English physician [[Leonard Colebrook]] at the [[Queen Charlotte's and Chelsea Hospital|Queen Charlotte's Maternity Hospital]] in London. Immediately after reading Domagk's paper, in 1935, Colebrook repeated the experiments on mice using both soluble Streptozon and the less soluble form and found that Streptozon was more effective but only in specific bacteria that caused [[puerperal fever]].<ref>{{Cite journal |last=Ellis |first=Harold |date=2011 |title=Leonard Colebrook and the treatment of puerperal sepsis |url=https://pubmed.ncbi.nlm.nih.gov/21378618 |journal=British Journal of Hospital Medicine |volume=72 |issue=2 |pages=109 |doi=10.12968/hmed.2011.72.2.109 |issn=1750-8460 |pmid=21378618}}</ref><ref>{{Cite journal |last=Dunn |first=P. M. |date=2008 |title=Dr Leonard Colebrook, FRS (1883-1967) and the chemotherapeutic conquest of puerperal infection |url=https://pubmed.ncbi.nlm.nih.gov/18426926 |journal=Archives of Disease in Childhood. Fetal and Neonatal Edition |volume=93 |issue=3 |pages=F246\u2013248 |doi=10.1136/adc.2006.104448 |issn=1468-2052 |pmid=18426926|s2cid=19923455 }}</ref> However, he found a serious side effect that the surviving mice developed severe [[Kidney disease|kidney damages]]. This discouraged him from human clinical trials, but he encountered one woman who was terminally ill from puerperal fever. Without other options of treatment, he gave the Streptozon that cured the woman in a couple of days. He tested the drug again on another woman with the same result, to which he remarked: \"Almost at once there was a surprising and most gratifying change.\"<ref name=\":7\" /> With M\u00e9ave Kenny, he treated 64 women and reported the experiments and clinical trials in 1936.<ref name=\":8\" /> The medical application was soon supported by other clinical cases and Prontosil became the major antibiotic for the next decade.<ref name=\":5\" />\n\nSulfonamides had revolutionary antibacterial effectiveness for their time, surpassing [[phage therapy]], but were later replaced by [[penicillin]], which showed both better effects and fewer [[Adverse drug reaction|side effects]] (sulfonamides can cause [[kidney stone]]s and changes in [[bone marrow]]). However, Domagk's work on sulfonamides eventually led to the development of the antituberculosis drugs [[thiosemicarbazone]] and [[isoniazid]], which helped to curb the epidemic of tuberculosis which swept Europe after World War II. Although Prontosil lost its popularity after the 1960s, its derivatives are continued to be used in several bacterial and viral infections,<ref>{{Cite journal |last1=Apayd\u0131n |first1=Sinem |last2=T\u00f6r\u00f6k |first2=Marianna |date=2019-08-15 |title=Sulfonamide derivatives as multi-target agents for complex diseases |url=https://pubmed.ncbi.nlm.nih.gov/31272793 |journal=Bioorganic & Medicinal Chemistry Letters |volume=29 |issue=16 |pages=2042\u20132050 |doi=10.1016/j.bmcl.2019.06.041 |issn=1464-3405 |pmid=31272793|s2cid=195807205 }}</ref> especially in the treatments of burns and urinary tract infections.<ref>{{Citation |last=Arivazhahan |first=Avinash |title=Sulfonamides, Quinolones, and Agents for Urinary Tract Infections |date=2021 |url=http://link.springer.com/10.1007/978-981-33-6009-9_53 |work=Introduction to Basics of Pharmacology and Toxicology |pages=807\u2013819 |editor-last=Paul |editor-first=Abialbon |place=Singapore |publisher=Springer Singapore |language=en |doi=10.1007/978-981-33-6009-9_53 |isbn=978-981-336-008-2 |s2cid=234297557 |access-date=2022-09-07 |editor2-last=Anandabaskar |editor2-first=Nishanthi |editor3-last=Mathaiyan |editor3-first=Jayanthi |editor4-last=Raj |editor4-first=Gerard Marshall}}</ref>\n\n=== Zephirol ===\nIn 1932, Domagk discovered the potential use of benzyldimethyldodecylammonium chloride as a powerful antimicrobial agent. After a series of tests with different bacteria, he published in 1935 as a disinfectant, naming it Zephirol.<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1935 |title=Eine neue Klasse von Desinfektionsmitteln |url=http://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1129654 |journal=DMW - Deutsche Medizinische Wochenschrift |language=de |volume=61 |issue=21 |pages=829\u2013832 |doi=10.1055/s-0028-1129654 |issn=0012-0472}}</ref> Domagk explained how Zephirol applied to the skin, such as before wearing gloves during surgery, could prevent infection.<ref>{{Cite journal |last1=Rahn |first1=Otto |last2=Van Eseltine |first2=William P. |date=1947 |title=Quaternary ammonium compounds |url=https://www.annualreviews.org/doi/10.1146/annurev.mi.01.100147.001133 |journal=Annual Review of Microbiology |language=en |volume=1 |issue=1 |pages=173\u2013192 |doi=10.1146/annurev.mi.01.100147.001133 |issn=0066-4227}}</ref> It led to a successful marketing as a common disinfectant. This was the discovery of [[quats]],<ref>{{Cite web |last=Lim |first=XiaoZhi |date=2022 |title=Do we know enough about the safety of quat disinfectants? |url=https://cen.acs.org/safety/consumer-safety/know-enough-safety-quat-disinfectants/98/i30 |access-date=2022-10-05 |website=cen.acs.org}}</ref> chemicals that are later used in a variety of consumer applications including as general [[antimicrobials]] (such as [[Detergent|detergents]] and [[Disinfectant|disinfectants]]), [[Fabric softener|fabric softeners]], and [[Hair conditioner|hair conditioners]].<ref>{{Cite journal |last=Bure\u0161 |first=Filip |date=2019 |title=Quaternary Ammonium Compounds: Simple in Structure, Complex in Application |url=http://link.springer.com/10.1007/s41061-019-0239-2 |journal=Topics in Current Chemistry |language=en |volume=377 |issue=3 |pages=14 |doi=10.1007/s41061-019-0239-2 |pmid=31062103 |s2cid=146809199 |issn=2365-0869}}</ref><ref>{{Cite journal |last1=Zubris |first1=Deanna L. |last2=Minbiole |first2=Kevin P. C. |last3=Wuest |first3=William M. |date=2017 |title=Polymeric Quaternary Ammonium Compounds: Versatile Antimicrobial Materials |url=https://pubmed.ncbi.nlm.nih.gov/27572084 |journal=Current Topics in Medicinal Chemistry |volume=17 |issue=3 |pages=305\u2013318 |doi=10.2174/1568026616666160829155805 |issn=1873-4294 |pmid=27572084}}</ref> \n\n=== Cancer therapy ===\nSince 1936, Domagk also focussed on cancer treatment.<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1936 |title=Die synthetisch hergestellten carcinogenen Substanzen und ihre Beziehungen zu physiologischen Produkten |url=http://link.springer.com/10.1007/BF01668053 |journal=Zeitschrift f\u00fcr Krebsforschung |language=de |volume=44 |issue=1 |pages=160\u2013186 |doi=10.1007/BF01668053 |s2cid=30564489 |issn=0171-5216}}</ref> In 1956, he reported the successful development of an anticancer drug which he designated E-39 (E for ethylenimine quinones).<ref name=\":9\" /> He showed that the compound could destroy cancer cells such as Yoshida sarcoma, [[Ehrlich carcinoma]] and Crocker sarcoma of mice and the Walker carcinoma of rats.<ref>{{Cite journal |last=Domagk |first=Gerhard |date=1956 |title=Histologische Ver\u00e4nderungen an experimentellen und menschlichen Tumoren nach Darreichung von Zytostatika 1 |url=http://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1115792 |journal=DMW - Deutsche Medizinische Wochenschrift |language=de |volume=81 |issue=21 |pages=801\u2013806 |doi=10.1055/s-0028-1115792 |pmid=13330468 |issn=0012-0472}}</ref><ref>{{Cite journal |last=Domagk |first=Gerhard |date=1958 |title=Chemotherapy of cancer by ethylenimino quinones: its foundations and problems |url=https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1958.tb42681.x |journal=Annals of the New York Academy of Sciences |language=en |volume=68 |issue=3 |pages=1197\u20131204 |doi=10.1111/j.1749-6632.1958.tb42681.x|pmid=13627772 |bibcode=1958NYASA..68.1197D |s2cid=30047404 }}</ref> He was aware that precision drugs would be required to target specific cancers, as he remarked:<blockquote>In therapy we will have to be satisfied, for the present at least, with a certain equilibrium between body cell and tumorous cell, even if the tumor cannot be completely eliminated. We will be satisfied if we ca slow down it growth, in order to preserve the life of a patient longer and under bearable conditions.<ref>{{Cite journal |last=Rotta |first=H. |date=1958 |title=Seventh Meeting of Nobel Prize Winners in Lindau |url=https://www.science.org/doi/10.1126/science.128.3329.905 |journal=Science |language=en |volume=128 |issue=3329 |pages=905\u2013913 |doi=10.1126/science.128.3329.905 |issn=0036-8075}}</ref></blockquote>Although the drug did not find way into prescription treatment of cancer, it was continued to be investigated<ref>{{Cite journal |last=Scholtissek |first=Christoph |date=1957 |title=\u00dcber die PH-Abh\u00e4ngigkeit bei der Einwirkung zweier \u00c4thyleniminchinone (Bayer E 39 und Bayer A 139) auf Nucleins\u00e4uren |url=https://doi.org/10.1007/BF00524536 |journal=Zeitschrift f\u00fcr Krebsforschung |language=de |volume=62 |issue=2 |pages=109\u2013111 |doi=10.1007/BF00524536 |doi-broken-date=9 October 2022 |issn=1432-1335}}</ref><ref>{{Cite journal |last=Gregl |first=Anton |date=1963 |title=Intrakavit\u00e4re Behandlung der Pleuritis carcinomatosa |url=http://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1112254 |journal=DMW - Deutsche Medizinische Wochenschrift |language=de |volume=88 |issue=30 |pages=1480\u20131484 |doi=10.1055/s-0028-1112254 |pmid=13950244 |issn=0012-0472}}</ref> and several related compounds are still under experimental studies.<ref>{{Citation |last1=Madhuswapnaja |first1=K. Jones |title=Design, Synthesis, and Biological Evaluation of Aziridynyl Quinone Derivatives |date=2021 |url=https://onlinelibrary.wiley.com/doi/10.1002/9781119640929.ch8 |work=Chemistry of Biologically Potent Natural Products and Synthetic Compounds |pages=205\u2013250 |editor-last=Shahid\u2010ul\u2010Islam |edition=1 |publisher=Wiley |language=en |doi=10.1002/9781119640929.ch8 |isbn=978-1-119-64092-9 |access-date=2022-10-05 |last2=Yennam |first2=Satyanarayana |last3=Chavali |first3=Murthy |s2cid=236235376 |editor2-last=Banday |editor2-first=Javid Ahmad}}</ref><ref>{{Cite journal |last1=Kumar |first1=P. Ravi |last2=Yennam |first2=Satyanarayana |last3=Raghavulu |first3=K. |last4=Velatooru |first4=Loka Reddy |last5=Kotla |first5=Siva Reddy |last6=Penugurti |first6=Vasudevarao |last7=Hota |first7=Prasanta K |last8=Behera |first8=Manoranjan |last9=Shree |first9=A. Jaya |date=2019 |title=Synthesis of Novel Diaziridinyl Quinone Isoxazole Hybrids and Evaluation of Their Anti-Cancer Activity as Potential Tubulin-Targeting Agents |url=http://www.thieme-connect.de/DOI/DOI?10.1055/a-0810-7033 |journal=Drug Research |language=en |volume=69 |issue=7 |pages=406\u2013414 |doi=10.1055/a-0810-7033 |pmid=30654398 |s2cid=58630060 |issn=2194-9379}}</ref><ref>{{Cite journal |last1=Swapnaja |first1=K. Jones M. |last2=Yennam |first2=Satyanarayana |last3=Chavali |first3=Murthy |last4=Poornachandra |first4=Y. |last5=Kumar |first5=C. Ganesh |last6=Muthusamy |first6=Krubakaran |last7=Jayaraman |first7=Venkatesh Babu |last8=Arumugam |first8=Premkumar |last9=Balasubramanian |first9=Sridhar |last10=Sriram |first10=Kiran Kumar |date=2016 |title=Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids |url=https://pubmed.ncbi.nlm.nih.gov/27089214 |journal=European Journal of Medicinal Chemistry |volume=117 |pages=85\u201398 |doi=10.1016/j.ejmech.2016.03.042 |issn=1768-3254 |pmid=27089214}}</ref>\n\n== Nobel Prize and issues ==\nIn 1939, Domagk was selected by the [[Nobel Foundation]] to receive the Nobel Prize in Physiology or Medicine for the discovery of Prontosil as an antibiotic, the first commercially available drug effective against [[bacterial infection]]s. However, the Nazi Germany banned him from attending the award ceremony. This was because [[Carl von Ossietzky]], an outspoken anti-Nazi pacifist, had won the [[Nobel Peace Prize]] in 1935, who which had angered the [[Nazi German government]]. Ossietzky was imprisoned and died in a concentration camp. In 1937, Adolf Hitler made an official decree that prohibited German nationals to accept the Nobel Prize.<ref name=\":0\" /><ref name=\"NobelBook\">\n{{cite book |last=Sch\u00fcck |first=Henrik |title=Nobel: The Man and His Prizes |author2=Ragnar Sohlman |author3=Anders \u00d6sterling |author4=G\u00f6ran Liljestrand |author5=Arne Westgren |author6=Manne Siegbahn |author7=August Schou |author8=Nils K. St\u00e5hle |publisher=Klara Civiltryckeri |year=1950 |editor=Nobel Foundation |editor-link=Nobel Foundation |location=Stockholm |pages=167\u2013179 |chapter=The Prize in Physiology and Medicine: The Nobel Prizes in Wartime}}</ref>\n\nOn 27 October 1939, Domagk received a telegram from the rector of the [[Karolinska Institute]] in Stockholm that he was to receive the Nobel Prize. He informed the rector of the University of M\u00fcnster, Walter Mevius, who immediately submitted a petition to the German authorities to allow Domagk to receive the award. Domagk himself wrote to the [[Hitler's Chancellery|NSDAP Office of the F\u00fchrer]], Hitler's headquarters, that should he be allowed to receive he award, he would donate 100,000 [[Deutsche Marks]] for the war cause.<ref name=\":0\" /> On 17 November, he was arrested by the [[Gestapo]] who detained him for a week.<ref>[[Thomas Hager]], ''The Demon Under the Microscope'' (2006) {{ISBN|1-4000-8213-7}} (cited in [https://www.npr.org/templates/story/story.php?storyId=6667754 \"The Saga of a Sulfa Drug Pioneer\"] \u2013 [[NPR]] ''[[Weekend Edition]]'' 23 December 2006)</ref><ref>[http://nobelprize.org/nobel_prizes/nobelprize_facts.html NobelPrize.org] {{webarchive|url=https://web.archive.org/web/20070202025710/http://nobelprize.org/nobel_prizes/nobelprize_facts.html|date=2 February 2007}}</ref><ref name=\"NobelBook\" /> He was released when he was verified that he supported the [[German National Socialism]] and was politically loyal. However, he was informed to communicate with [[Karolinska Institute]] only through the government departments such as the Ministry of Education or Foreign Office, and forced to decline the award.<ref name=\":0\" /> It was officially announced in Berlin that Domagk had \"rather regretfully declined\" the award.<ref name=\":9\" />\n\nTwo years after the end of World War II and the Nazi regime, the Nobel Foundation gave the Nobel medallion and a diploma to Domagk in 1947. However, the monetary prize was not given as it was already returned to the foundation.<ref name=\":4\">{{Cite book |last=Rifkind |first=David |url=https://www.worldcat.org/oclc/162572834 |title=The Nobel Prize Winning Discoveries in Infectious Diseases |date=2005 |publisher=Elsevier/Academic |isbn=978-0-12-369353-2 |location=London |pages=39 |language=en |chapter=Prontosil and the sulfonamides |oclc=162572834}}</ref>\n\n== Awards and honours ==\nDomagk was awarded the 1939 Nobel Prize in Physiology or Medicine. In the same year, Domagk was also awarded the [[Cameron Prize for Therapeutics of the University of Edinburgh]]. In 1941 Domagk was awarded the ''Medaglia Paterno'' (Rome) by the [[Kingdom of Italy]] and also the Von-Klebelsberg-Medal and Prize by the [[Kingdom of Hungary (1920\u201346)|Kingdom of Hungary]]. He became a member of the [[German Academy of Sciences Leopoldina]] in 1942. \n\nAfter the war, in 1947, Domagk was finally able to receive his Nobel Prize,<ref>{{cite journal |last1=Chorba |first1=Terence |date=March 2018 |title=Peace, Liberty, Mycobacteria, and Tuberculosis Mortality |journal=Emerg Infect Dis |volume=24 |issue=3 |pages=611\u2013612 |doi=10.3201/eid2403.AC2403 |pmc=5823360}}</ref> but not the monetary portion of the prize due to the time that had elapsed. In 1951, he was one of seven Nobel Laureates who attended the 1st [[Lindau Nobel Laureate Meetings|Lindau Nobel Laureate Meeting]].<ref>{{Cite web |title=1st Lindau Nobel Laureate Meeting - Laureates |url=http://www.mediatheque.lindau-nobel.org/laureates/meeting-1951 |access-date=2018-01-09 |website=www.mediatheque.lindau-nobel.org}}</ref> He received the El Soleil del Per\u00fa in 1952, the Pour le m\u00e9rite f\u00fcr Wissenschaften und K\u00fcnste in 1952, the Spanish Civil de Sanidad in 1953, the del Lobertador from the Republic of Venezuela in 1957, the Medal of the Rising Sun 2nd Class from Japan in 1960, the Grand Cross with Star of the Order of Merit of the Federal Republic of Germany in 1955. In 1952, he was elected chairman of the German Society of Pathology.<ref name=\":0\" />\n\nDomagk became a Foreign Member of the [[Royal Society]] in 1959; his short biography was published by the Royal Society in 1964.<ref name=\"frs\">{{Cite journal |last1=Colebrook |first1=Leonard |author-link=Leonard Colebrook |year=1964 |title=Gerhard Domagk 1895-1964 |journal=[[Biographical Memoirs of Fellows of the Royal Society]] |volume=10 |pages=38\u201350 |doi=10.1098/rsbm.1964.0003 |doi-access=free}}</ref><ref name=\"NobelBook\" />\n\nDomagkpark, a public park, and Domagkstra\u00dfe, a road, in Munich are named after Domagk. In M\u00fcnster, a research foundation called Krebsforschung Professor Dr. Gerhard Domagk (Cancer Research Professor Dr. Gerhard Domagk) was established in 1961, and Gerhard-Domagk-Institut f\u00fcr Pathologie (Gerhard Domagk Institute of Pathology) is created in the University of M\u00fcnster.<ref name=\":0\" /> \n\n==References==\n{{Reflist}}\n\n==External links==\n* {{Nobelprize}} including the Nobel Lecture on 12 December 1947 ''Further Progress in Chemotherapy of Bacterial Infections''\n* [https://www.bayer.com/en/history/gerhard-domagk Biography at Bayer]\n{{Nobel Prize in Physiology or Medicine Laureates 1926-1950}}\n{{1939 Nobel Prize winners}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Domagk, Gerhard}}\n[[Category:1895 births]]\n[[Category:1964 deaths]]\n[[Category:People from \u015awiebodzin County]]\n[[Category:German bacteriologists]]\n[[Category:Nobel laureates in Physiology or Medicine]]\n[[Category:German pathologists]]\n[[Category:German Nobel laureates]]\n[[Category:People from the Province of Brandenburg]]\n[[Category:Recipients of the Pour le M\u00e9rite (civil class)]]\n[[Category:University of Greifswald faculty]]\n[[Category:University of Kiel alumni]]\n[[Category:University of M\u00fcnster faculty]]\n[[Category:German Army personnel of World War I]]\n[[Category:Foreign Members of the Royal Society]]\n[[Category:Bayer people]]"}}}]}}}}